Ocugen, Inc. (OCGN) analyst actions
Rating and price-target actions on OCGN in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the OCGN overview →
4 measured OCGN analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease | Press release | +0.23% | -0.66% | |
| Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy | Press release | +2.28% | +9.49% | |
| Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy | Press release | +5.87% | +17.31% | |
| Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease | Press release | -1.41% | -2.82% |
Keep exploring
More OCGN: earnings → · SEC filings → · OCGN overview →